The Search for new anticancer drugs
著者
書誌事項
The Search for new anticancer drugs
(Cancer biology and medicine, CABM 03)
Kluwer Academic Publishers, c1992
大学図書館所蔵 全3件
  青森
  岩手
  宮城
  秋田
  山形
  福島
  茨城
  栃木
  群馬
  埼玉
  千葉
  東京
  神奈川
  新潟
  富山
  石川
  福井
  山梨
  長野
  岐阜
  静岡
  愛知
  三重
  滋賀
  京都
  大阪
  兵庫
  奈良
  和歌山
  鳥取
  島根
  岡山
  広島
  山口
  徳島
  香川
  愛媛
  高知
  福岡
  佐賀
  長崎
  熊本
  大分
  宮崎
  鹿児島
  沖縄
  韓国
  中国
  タイ
  イギリス
  ドイツ
  スイス
  フランス
  ベルギー
  オランダ
  スウェーデン
  ノルウェー
  アメリカ
注記
Includes bibliographical references and index
内容説明・目次
内容説明
Most of the anti-cancer drugs in use today were discovered by happy accident rather than design, yet the rational design of better anti-cancer drugs remains a cherished goal, and one of the most important challenges facing medical science.
This book represents a compilation of views and progress reports which illustrate the diversity of approaches to the problem. Recent research has confirmed the belief that critical genetic changes are at work in cancer cells. The genome, then (DNA in biochemical terms), surely represents a critical target for specific chemotherapy of cancer, and several chapters address the issue of attacking DNA, gene targetting, and the like. Others deal with principles of rational design, exploitation of novel modalities and targets, or the nuts and bolts of antitumour drug testing. While no attempt has been made to provide a comprehensive coverage of this wide-ranging and vitally important subject, the present volume in the series will provide much food for thought.
目次
1. Is there a future for the small molecule in developmental cancer chemotherapy?.- 2. The role of medicinal chemistry in the discovery of DNA-active anticancer drugs: from random searching, through lead development, to de novo design.- 3. In vitro systems for anticancer drug testing.- 4. Tumour hypoxia: challenges for cancer chemotherapy.- 5. Computer modelling and drug design.- 6. Differentiation inducers and their potential use in the treatment of acute myelogenous leukaemia.- 7. Angiosuppression.- 8. Preclinical evaluation and phase I trials.- 9. Evaluation: how should a new treatment be evaluated?.- 10. Oncogene-targeted antisense oligonucleotides: tools for genetic analysis or new anticancer drugs?.
「Nielsen BookData」 より